Valvular & structural heart disease
Design and rationale of the prospective, randomized, controlled trial to assess the management of moderate aortic stenosis by clinical surveillance or transcatheter aortic valve replacement: The PROGRESS Trial
- prospective, open-label, randomized, controlled, multicenter trial
- design and rationale
- stratified by site, left ventricular ejection fraction, and peak jet velocity
- followed annually through 10 years
+3 more
- design and rationale
- stratified by site, left ventricular ejection fraction, and peak jet velocity
- followed annually through 10 years
Study context
- Population
- Patients with moderate aortic stenosis (AS) and at-risk featuresplanned enrolment
- Participants
- up to 750 patients
- Planned comparison
- early intervention with transfemoral TAVR vs clinical surveillance
- Primary endpoint
- composite of death or heart failure event with or without hospitalization (primary effectiveness endpoint)
- Follow-up
- 2 years
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Design and rationale of the prospective, randomized, controlled trial to assess the management of moderate aortic stenosis by clinical surveillance or transcatheter aortic valve replacement: The PROGRESS Trial. Am Heart J. Published 25 March 2026. doi:10.1016/j.ahj.2026.107433
Summarised from the published abstract; every number is checked against it